ClinicalTrials.gg
Not yet recruitingNCT07717762Updated Jul 21, 2026

Building a Swiss Pain Registry: A National Framework for Acute and Chronic Pain Assessment

An observational study in Chronic Pain and Acute Pain, sponsored by Insel Gruppe AG, University Hospital Bern. Not yet recruiting at 1 site in Switzerland. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Insel Gruppe AG, University Hospital Bern · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Chronic Pain with a site in Switzerland — 9 open to participants now, 9 under way, none of them phase 3. Chronic Pain · Switzerland.

Planned enrollment
5th of 21
500 · median 168
Started
2026
with 3 others
Observational
21 of 43
6 open now
Registered
43rd of 43
by date
Lead sponsor
3 of 43
Insel Gruppe AG, University Hospital Bern

Among the 43 studies in Chronic Pain with a site in Switzerland, this one is the 5th largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2026, is one of 21 observational ones, and was the 43rd registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

9 of the 43 studies in Chronic Pain with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Chronic Pain with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this observational registry is to systematically collect and analyse real-world clinical and patient-reported data in individuals receiving treatment for acute and chronic pain. The main questions it aims to answer are: How do pain intensity, functional status, and quality of life evolve over time in patients with acute and chronic pain? How are different routine clinical treatment approaches associated with patient-reported outcomes in real-world clinical practice? Participants already receiving standard care for pain management will have routine clinical data recorded as part of their treatment and will be asked to complete standardized questionnaires on pain intensity, functional status, and quality of life at multiple time points during treatment and follow-up. Data are collected using a secure electronic system and are pseudonymised prior to analysis in accordance with Swiss data protection regulations.

Read the detailed description

This prospective, observational registry study aims to establish a standardized, multidomain digital assessment platform for patients with acute and chronic pain within routine outpatient care at the University Hospital Bern. The registry is designed as a scalable national infrastructure with planned expansion to additional Swiss pain clinics. The primary objective is to evaluate feasibility, acceptability, and data quality of a digital baseline assessment integrating validated patient-reported outcome measures (PROMs) across pain, functional, psychological, sleep, and quality-of-life domains. Secondary objectives include the description of baseline patient profiles, exploration of longitudinal outcomes at 6, 12, 18, and 24 months, assessment of operational feasibility of follow-up assessments, and investigation of sex- and gender-related differences. In addition, optional treatment-triggered follow-up modules may be used after therapeutic interventions to capture short-term outcomes, side effects, and patient-reported treatment satisfaction. Data are collected prospectively via REDCap and include both routinely documented clinical data and additional patient-reported outcomes. The study duration is 36 months, including a 12-month recruitment phase and 24 months of follow-up per participant.

03

Conditions studied

  • Chronic Pain
  • Acute Pain
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population consists of patients referred for interdisciplinary outpatient assessment and management of acute and chronic pain. The registry includes paediatric and adult patients of all genders across the full spectrum of acute and chronic pain conditions in routine clinical care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed by the participant or legal guardian for minors.
  • Diagnosis of acute or chronic pain (chronic pain defined as pain lasting ≥ 3 months), including nociceptive, neuropathic, or mixed pain conditions.
  • Referral for interdisciplinary outpatient pain assessment or treatment.
  • Sufficient proficiency in German, French, Italian, or English to complete digital assessments (parental proxy allowed for paediatric participants if needed).
  • All age groups included.

Exclusion criteria

Exclusion Criteria:

  • Lack of capacity to provide or absence of a legal guardian for minors.
  • Inability to understand study languages and complete assessments even with assistance.
  • Acute life-threatening conditions precluding participation.
  • Site-specific safety considerations as determined by treating clinician.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • Pain Registry Cohort

    Participants enrolled in the Swiss Pain Registry. The cohort includes patients with acute and chronic pain receiving routine clinical care. No intervention is assigned; data are collected observationally through clinical documentation and patient-reported outcome measures over a follow-up period of up to 24 months.

06

What researchers measure

Primary outcomes

  1. Feasibility of baseline assessment

    Feasibility is defined as the proportion of eligible participants who complete the full multidomain digital baseline assessment across all predefined domains.

    Time frame: Baseline (at enrollment)

  2. Data quality of baseline assessment

    Data quality will be evaluated by completeness of core variables of the multidomain digital baseline assessment (percentage of missing data at item and domain level).

    Time frame: Baseline (at enrollment)

Secondary outcomes

  1. Pain intensity

    Pain intensity measured using the Brief Pain Inventory (BPI). The BPI uses numeric rating scales from 0 to 10, where higher scores indicate greater pain intensity.

    Time frame: Baseline, 6, 12, 18, 24 months

  2. Pain interference

    Pain interference measured using the Brief Pain Inventory (BPI). The BPI uses numeric rating scales from 0 to 10, where higher scores indicate greater pain interference.

    Time frame: Baseline, 6, 12, 18, 24 months

  3. Neuropathic pain screening

    Neuropathic pain symptoms assessed using the Douleur Neuropathique 4 (DN4) questionnaire. Total scores range from 0 to 10, with higher scores indicating greater likelihood of neuropathic pain.

    Time frame: Baseline, 6, 12, 18, 24 months

  4. Neuropathic pain symptom profile

    Neuropathic pain symptom profile assessed using the Neuropathic Pain Symptom Inventory (NPSI). Total scores range from 0 to 100, with higher scores indicating more severe neuropathic pain symptoms.

    Time frame: Baseline, 6, 12, 18, 24 months

  5. Functional disability

    Functional disability assessed using the Oswestry Disability Index (ODI). Total scores range from 0 to 100, with higher scores indicating greater disability.

    Time frame: Baseline, 6, 12, 18, 24 months

  6. Work ability

    Work ability assessed using the Work Ability Index (WAI). Total scores range from 7 to 49, with higher scores indicating better work ability.

    Time frame: Baseline, 6, 12, 18, 24 months

  7. Psychological distress

    Psychological distress (anxiety, depression) assessed using the Patient Health Questionnaire-4 (PHQ-4). Total scores range from 0 to 12, with higher scores indicating greater anxiety and depressive symptoms.

    Time frame: Baseline, 6, 12, 18, 24 months

  8. Pain catastrophizing

    Pain catastrophizing assessed using the Pain Catastrophizing Scale (PCS). Total scores range from 0 to 52, with higher scores indicating greater catastrophizing.

    Time frame: Baseline, 6, 12, 18, 24 months

  9. Sleep quality

    Sleep quality assessed using the Bernese Sleep Health Questionnaire (BSHQ). Higher scores indicate worse sleep quality.

    Time frame: Baseline, 6, 12, 18, 24 months

  10. Health-related quality of life

    Health-related quality of life assessed using the World Health Organization Quality of Life - BREF (WHOQOL-BREF). Total scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: Baseline, 6, 12, 18, 24 months

  11. Global patient-reported improvement

    Global improvement measured using the Patient Global Impression of Change (PGI-C). The PGI-C is a 7-point scale ranging from "very much worse" to "very much improved".

    Time frame: 6, 12, 18, 24 months

  12. Follow-up completion and adherence

    Completion rates of PROM assessments, adherence to follow-up schedules, and workflow integration indicators including proportion of home versus clinic completion and completion time.

    Time frame: 6, 12, 18, 24 months

Other outcomes

  1. Post-intervention pain intensity and interference

    Pain intensity and interference assessed approximately one week after therapeutic interventions using the Brief Pain Inventory (BPI; 0-10 scale, higher scores indicate worse pain and interference).

    Time frame: Approximately 1 week after intervention (post-intervention follow-up; variable depending on clinical trigger)

  2. Post-intervention side effects and adverse events

    Patient-reported side effects and adverse events collected approximately one week after intervention using structured questionnaire items.

    Time frame: Approximately 1 week after intervention (post-intervention follow-up; variable depending on clinical trigger)

  3. Post-intervention treatment satisfaction and perceived effectiveness

    Patient-reported satisfaction, perceived effectiveness, and acceptability of the intervention assessed approximately one week after treatment using structured questionnaire items.

    Time frame: Approximately 1 week after intervention (post-intervention follow-up; variable depending on clinical trigger)

07

Study locations

1 site
  • Universitätsklinik für Anästhesiologie und Schmerzmedizin, Inselspital, Universitätsspital Bern
    Bern, Canton of Bern 3010, Switzerland
    • · Contactschmerz@insel.ch · +41 31 632 21 11
    • Michael A Harnik, MD · Principal investigator
    • Melissa L Flury, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data (IPD) collected within this registry are currently not planned for routine sharing with external researchers. Any future sharing of de-identified or coded datasets will be considered on a case-by-case basis and will require appropriate ethical approval, data transfer agreements, and compliance with applicable Swiss data protection regulations and institutional policies. No direct identifiers will be shared at any time.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Aug 2029, 37 months later.

Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 37 months is above that.

Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 21, 2026
StartEst.
Jul 15, 2026
Primary completionEst.
Aug 15, 2029
CompletionEst.
Aug 15, 2029
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07717762
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Jul 15, 2026 (estimated)
Primary completion
Aug 15, 2029 (estimated)
Completion
Aug 15, 2029 (estimated)
Last update
Jul 21, 2026

Study contacts

Michael A Harnik, MD
Contact
michael.harnik@insel.ch
+41 31 632 30 27
Michael A Harnik, MD
principal investigator · Universitätsklinik für Anästhesiologie und Schmerzmedizin, Inselspital, Universitätsspital Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion